{
    "ticker": "STXE",
    "name": "Sutro Biopharma, Inc.",
    "description": "Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing next-generation protein therapeutics for the treatment of cancer and other serious diseases. Founded in 2003, Sutro leverages its proprietary cell-free protein synthesis platform to create a diverse pipeline of drug candidates that include antibody-drug conjugates (ADCs) and other novel therapeutics. The company's unique approach allows for greater flexibility and efficiency in the drug development process, enabling the rapid production of highly complex proteins. Sutro is committed to advancing its programs through various stages of clinical development, with several candidates currently undergoing trials. The company's lead product candidate, STRO-001, is an ADC targeting CD74 for the treatment of hematologic malignancies. Sutro Biopharma aims to address unmet medical needs by harnessing the potential of its platform to create innovative therapies that improve patient outcomes. With a dedicated team and strategic partnerships, Sutro continues to push the boundaries of protein therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2003",
    "website": "https://www.sutrobio.com",
    "ceo": "William Newell",
    "social_media": {
        "twitter": "https://twitter.com/sutrobio",
        "linkedin": "https://www.linkedin.com/company/sutro-biopharma/"
    },
    "investor_relations": "https://investors.sutrobio.com",
    "key_executives": [
        {
            "name": "William Newell",
            "position": "CEO"
        },
        {
            "name": "Lynn Kirkpatrick",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antibody-Drug Conjugates",
            "products": [
                "STRO-001",
                "STRO-002"
            ]
        },
        {
            "category": "Protein Therapeutics",
            "products": [
                "Novel Therapeutics"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sutro Biopharma, Inc. | Innovative Protein Therapeutics",
        "meta_description": "Explore Sutro Biopharma, Inc., a leader in protein therapeutics and drug development. Learn about our innovative pipeline and commitment to cancer treatment.",
        "keywords": [
            "Sutro Biopharma",
            "Biotechnology",
            "Cancer Treatment",
            "Antibody-Drug Conjugates",
            "Protein Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Sutro Biopharma specialize in?",
            "answer": "Sutro Biopharma specializes in developing next-generation protein therapeutics, particularly antibody-drug conjugates."
        },
        {
            "question": "Who is the CEO of Sutro Biopharma?",
            "answer": "William Newell is the CEO of Sutro Biopharma, Inc."
        },
        {
            "question": "Where is Sutro Biopharma headquartered?",
            "answer": "Sutro Biopharma is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Sutro's main product candidates?",
            "answer": "Sutro's main product candidates include STRO-001 and STRO-002, which are focused on treating cancer."
        },
        {
            "question": "When was Sutro Biopharma founded?",
            "answer": "Sutro Biopharma was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "ALNY",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "JNJ",
        "PFE"
    ]
}